Spots Global Cancer Trial Database for Telotristat Etiprate for Carcinoid Syndrome Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Telotristat Etiprate for Carcinoid Syndrome Therapy
Official Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Study ID: NCT02063659
Conditions
Study Description
Brief Summary: The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Lexicon Investigational Site, Stanford, California, United States
Lexicon Investigational Site, Orlando, Florida, United States
Lexicon Investigational Site, Iowa City, Iowa, United States
Lexicon Investigational Site, Lexington, Kentucky, United States
Lexicon Investigational Site, Boston, Massachusetts, United States
Lexicon Investigational Site, Buffalo, New York, United States
Lexicon Investigational Site, New York, New York, United States
Lexicon Investigational Site, Philadelphia, Pennsylvania, United States
Lexicon Investigational Site, Kogara, New South Wales, Australia
Lexicon Investigational Site, St. Leonards, New South Wales, Australia
Lexicon Investigational Site, Herston, Queensland, Australia
Lexicon Investigational Site, East Melbourne, Victoria, Australia
Lexicon Investigational Site, Edegem, , Belgium
Lexicon Investigational Site, Gent, , Belgium
Lexicon Investigational Site, Yvoir, , Belgium
Lexicon Investigational Site, Calgary, Alberta, Canada
Lexicon Investigational Site, Halifax, Nova Scotia, Canada
Lexicon Investigational Site, Clichy, , France
Lexicon Investigational Site, Lille, , France
Lexicon Investigational Site, Lyon, , France
Lexicon Investigational Site, Marseille, , France
Lexicon Investigational Site, Strasbourg, , France
Lexicon Investigational Site, Villejuif, , France
Lexicon Investigational Site, Bad Berka, , Germany
Lexicon Investigational Site, Berlin, , Germany
Lexicon Investigational Site, Hamburg, , Germany
Lexicon Investigational Site, Heidelberg, , Germany
Lexicon Investigational Site, Lubeck, , Germany
Lexicon Investigational Site, Mainz, , Germany
Lexicon Investigational Site, Marburg, , Germany
Lexicon Investigational Site, Munich, , Germany
Lexicon Investigational Site, Neuss, , Germany
Lexicon Investigational Site, Jerusalem, , Israel
Lexicon Investigational Site, Amsterdam, Noord-Holland, Netherlands
Lexicon Investigational Site, Amsterdam, Noord-Holland, Netherlands
Lexicon Investigational Site, Noord Brahant, , Netherlands
Lexicon Investigative Site, Rotterdam, , Netherlands
Lexicon Investigational Site, Barcelona, , Spain
Lexicon Investigational Site, Barcelona, , Spain
Lexicon Investigational Site, Madrid, , Spain
Lexicon Investigational Site, Madrid, , Spain
Lexicon Investigational Site, Sevilla, , Spain
Lexicon Investigational Site, Uppsala, , Sweden
Lexicon Investigational Site, Basingstoke Hampshire, , United Kingdom
Lexicon Investigational Site, Coventry, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, London, , United Kingdom
Lexicon Investigational Site, Manchester, , United Kingdom
Lexicon Investigational Site, Newcastle upon Tyne, , United Kingdom
Contact Details
Name: Pablo Lapuerta, MD
Affiliation: Lexicon Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
